Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Company Announcement - Minerva Neurosciences, Inc. will participate in The Stifel 2026 Virtual CNS Forum on March 17-18, 2026, with Remy Luthringer, PhD, serving as Executive Chairman & CEO [1] - The presentation is scheduled for March 18 at 8:30 AM ET, and a replay will be available for ninety days following the event [2] Company Overview - Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders [3] - The company is initiating a confirmatory Phase 3 trial with roluperidone aimed at addressing negative symptoms of schizophrenia [3]